Surrogate

Tannenbaum Helpern Announces Promotions to Partnership and Elevation to Firm Leadership

Retrieved on: 
Tuesday, January 2, 2024

NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Tannenbaum Helpern is pleased to announce the promotion of Amanda M. Leone and Andrew P. Yacyshyn to partner, and the elevation of Michele Itri to Co-Chair of the Firm's Investment Management Practice.

Key Points: 
  • "We are thrilled to welcome Amanda and Andrew to the partnership," said Tannenbaum Helpern Managing Partner, Andrew W. Singer.
  • Michele is an outstanding lawyer whose leadership is recognized inside and outside the Firm."
  • Andrew Yacyshyn commented, "Tannenbaum Helpern is a very special law firm.
  • Having spent my entire career as an attorney with the Firm, I am exceptionally proud to join the partnership."

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

Retrieved on: 
Wednesday, January 25, 2023

Atacicept is the Company’s potential best-in-class, disease-modifying dual inhibitor of the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL).

Key Points: 
  • Atacicept is the Company’s potential best-in-class, disease-modifying dual inhibitor of the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL).
  • A live question and answer session will follow the formal presentation.
  • Dr. Barratt leads the Renal Research Group within the College of Life Sciences, University of Leicester.
  • His research is focused on a bench to bedside approach to improving our understanding of the pathogenesis of IgAN, a common global cause of kidney failure.

ATMOFIZER TECHNOLOGIES INC. ANNOUNCES HVAC MARKET DEVELOPMENT AND THIRD QUARTER 2022 FINANCIAL RESULTS

Retrieved on: 
Tuesday, November 29, 2022

VANCOUVER,BC, Nov. 29, 2022 /PRNewswire/ - Atmofizer Technologies Inc.(the"Company"or"Atmofizer") (CSE: ATMO) (Frankfurt: J3K)(OTCQB: ATMFF) is pleased to announce its recent progress in developing its technology for the HVAC market and its financial results for the quarter ended September 30, 2022.

Key Points: 
  • VANCOUVER,BC, Nov. 29, 2022 /PRNewswire/ - Atmofizer Technologies Inc.(the"Company"or"Atmofizer") (CSE: ATMO) (Frankfurt: J3K)(OTCQB: ATMFF) is pleased to announce its recent progress in developing its technology for the HVAC market and its financial results for the quarter ended September 30, 2022.
  • The design can be easily adapted to expand beyond the residential HVAC market to service commercial, industrial and agricultural applications.
  • The HVAC solution has been designed to scale to other HVAC applications with an asset light strategy that will target existing HVAC suppliers and manufacturers with existing distribution and scale.
  • The Company plans to market this patent to be licensed by air purification device manufacturers, HVAC suppliers and service companies.

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

Retrieved on: 
Thursday, November 17, 2022

BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host a key opinion leader (KOL) webinar on IgA nephropathy (IgAN), a common cause of kidney failure. The webinar will be held on Monday, November 28, 2022 at 2:00pm ET.

Key Points: 
  • Recent data presented by Dr. Barratt at the American Society of Nephrology (ASN) Kidney Week 2022 showed atacicept reduced immune complex levels in patients with IgAN.
  • In addition, the Vera Therapeutics leadership team will provide an overview of the ongoing Phase 2b ORIGIN trial of atacicept in IgAN and the Companys pipeline.
  • If the data from the ORIGIN trial are supportive, Vera Therapeutics expects to initiate a pivotal Phase 3 clinical trial of atacicept in 2023.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.

ATMOFIZER TECHNOLOGIES INC. Announces LATEST Independent test results

Retrieved on: 
Thursday, August 25, 2022

The Food and Drug Administration (FDA) has not evaluated Atmofizer technology.

Key Points: 
  • The Food and Drug Administration (FDA) has not evaluated Atmofizer technology.
  • Atmofizer ONE has not been reviewed or approved by the FDA.
  • Atmofizer's consumer and industrial solutions are based on its patent-protected and patent pending technology for ultrafine particle agglomeration and neutralization.
  • Atmofizer plans to disrupt the air treatment industry by improving air safety and purification efficiency while lowering customers' operational costs.

RGF® Environmental Group Announces Results for Aerosol Treatment Technology Evaluation With Photocatalytic Device in EPA Independent Study

Retrieved on: 
Wednesday, November 10, 2021

EPA utilized its specialized Aerosol Test Facility in Research Triangle Park, NC, and its experience in conducting research with aerosol treatment technologies recently named RGF as a leader for control of MS2 (Surrogate for SARS-CoV-2) using its photocatalytic devices.The test used both the PHI-PKG5 and PHI-PKG9.

Key Points: 
  • EPA utilized its specialized Aerosol Test Facility in Research Triangle Park, NC, and its experience in conducting research with aerosol treatment technologies recently named RGF as a leader for control of MS2 (Surrogate for SARS-CoV-2) using its photocatalytic devices.The test used both the PHI-PKG5 and PHI-PKG9.
  • The test concluded that both PHI-PKG5 and PHI-PKG9 resulted in reduced levels of MS2 by 93% over the control in 90 minutes.
  • RGF is an ISO 9001:2015 certified research and innovation company, holding numerous patents for wastewater treatment systems, air purifying devices, and food sanitation systems.
  • For more information about the third-party study or to schedule an interview, please contact Malia Powers with PowerOn Marketing at [email protected] or 813-763-7488.

American Influencer Council Debuts "Creators With Influence" An Original Audio & Video Series On International Podcast Day

Retrieved on: 
Thursday, September 30, 2021

NEW YORK, Sept. 30, 2021 /PRNewswire/ --Recognizing the importance of showcasing small business excellence within the creator community, the American Influencer Council AIC unveils an original new series, "Creators with Influence," a multimedia vodcast, on International Podcast Day.

Key Points: 
  • NEW YORK, Sept. 30, 2021 /PRNewswire/ --Recognizing the importance of showcasing small business excellence within the creator community, the American Influencer Council AIC unveils an original new series, "Creators with Influence," a multimedia vodcast, on International Podcast Day.
  • "It's mission-critical for the AIC to support professional development and to produce programming that helps destigmatize the business of influencing.
  • AKG is a pioneer in professional audio technology, and the AKG Lyra Microphone delivers ultra HD audio quality to the recording of the series.
  • The American Influencer CouncilAIC is the sole 501(c)(6) not-for-profit membership trade association in the U.S., created by and for career creators.

C-Path's Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint

Retrieved on: 
Wednesday, June 17, 2020

Qualification as a surrogate or reasonably likely surrogate endpoint would allow drug sponsors to pursue accelerated approval, removing a significant barrier to kidney transplant drug development.

Key Points: 
  • Qualification as a surrogate or reasonably likely surrogate endpoint would allow drug sponsors to pursue accelerated approval, removing a significant barrier to kidney transplant drug development.
  • The iBox Scoring System, developed by the Paris Transplant Group, is the first tool of its kind to seek regulatory qualification for use in kidney transplant clinical trials.
  • To date, no biomarkers have been qualified for use as a surrogate or reasonably likely surrogate endpoint in any therapeutic area.
  • The iBox Scoring System has been extensively validated for use in the treatment of individual patients in the clinical care setting.

Surrogate Company Founder Aims for Even Better Care of Surrogate Mothers After Giving Birth to Her Own Child

Retrieved on: 
Monday, December 9, 2019

LOS ANGELES, Dec. 9, 2019 /PRNewswire/ -- Joy Millan, the founder of the Southern California-based surrogate enterprise, Joy of Life, has elevated the company's mission to provide better care for surrogate mothers after giving birth to a boy recently.

Key Points: 
  • LOS ANGELES, Dec. 9, 2019 /PRNewswire/ -- Joy Millan, the founder of the Southern California-based surrogate enterprise, Joy of Life, has elevated the company's mission to provide better care for surrogate mothers after giving birth to a boy recently.
  • Summarizing the journey of her pregnancy, Joy said, "I suddenly started to better understand a lot of people.
  • The emotional fluctuation was a burden for me as well as my family, and I'm sure there's even more pressure for surrogate mothers.
  • Apart from support from the surrogate mother's family, our agency and the intended parents must also help as much as we can.

Omega Family Surrogates Recounts the Emotional Surrogacy Process of Intended Parents

Retrieved on: 
Wednesday, July 17, 2019

Across the globe, more and more Intended Parents are electing to have a child through the surrogacy process.

Key Points: 
  • Across the globe, more and more Intended Parents are electing to have a child through the surrogacy process.
  • An interview with an Intended Parent who recently found a surrogate through Omega Family Global helps to shed light on this life-changing process.
  • Omega Family Surrogates help Intended Parents find and work with an Omega Surrogate and her family through the entire process.
  • After Intended Parents begin the process, they are assigned a caseworker and begin reviewing profiles of potential Omega Surrogates.